. Author manuscript; available in PMC: 2012 Apr 1.

Published in final edited form as: Circ Cardiovasc Genet. 2011 Feb 15;4(2):179–187. doi: 10.1161/CIRCGENETICS.110.957662

Table 2.

Cardiovascular outcome measures during placebo and dexmedetomidine infusions.

	Placebo	Dexmedetomidine	ΔAUC	P-value
AUC_SBP, mmHg*hr	171.3±14.1	160.2±12.4	−11.1±6.3	<0.001
AUC_DBP, mmHg*hr	103.7±9.1	95.7±8.0	−8.0±5.8	<0.001
AUC_HR, bpm*hr	97.5±12.1	95.2±12.4	−2.3±5.6	0.001
AUC_NE, pg*hr/mL	346.8±125.1	247.9±108.2	−98.9±76.0	<0.001
AUC_Epi, pg*hr/mL	35.8±21.9	32.9±20.2	−3.0±10.7	0.028

AUC=area under the curve; SBP=systolic blood pressure, DBP=diastolic BP, HR=heart rate, NE=norepinephrine, Epi=epinephrine, ΔAUC=difference in AUC between dexmedetomidine and placebo infusions.